CERx Pharmacy Partners, LP v. Provider Meds, LP (In re Providerx of Grapevine, LLC)

507 B.R. 132
CourtUnited States Bankruptcy Court, N.D. Texas
DecidedMarch 13, 2014
DocketBankruptcy No. 12-38039-BJH; Adversary No. 13-03015-BJH
StatusPublished
Cited by7 cases

This text of 507 B.R. 132 (CERx Pharmacy Partners, LP v. Provider Meds, LP (In re Providerx of Grapevine, LLC)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CERx Pharmacy Partners, LP v. Provider Meds, LP (In re Providerx of Grapevine, LLC), 507 B.R. 132 (Tex. 2014).

Opinion

MEMORANDUM OPINION GRANTING MOTION FOR RECONSIDERATION AND, UPON RECONSIDERATION, ADDRESSING MOTIONS FOR PARTIAL SUMMARY JUDGMENT

BARBARA J. HOUSER, Bankruptcy Judge.

Before the Court are the Plaintiff’s Amended Motion for Reconsideration or New Trial and Brief (the “Motion for Reconsideration”) [Dkt. No. 136] filed by CERx Pharmacy Partners, LP (“CERx”) in which CERx requests that this Court modify its Memorandum, Opinion entered August 2, 2013 (the “Original Memorandum Opinion”), the Trustees’ Response to Plaintiffs Amended Motion for Reconsideration or New Trial [Dkt. No. 139] filed by the Chapter 7 trustees of the various debtor-Defendants’ bankruptcy estates (collectively, the “Trustees”),1 and the various replies and post-hearing briefs related thereto. The Court held a hearing on the Motion for Reconsideration on January 8, 2013. At the conclusion of the hearing, the Court ordered additional briefing on several issues. The last of those briefs was [140]*140filed on January 17, 2014. The Motion for Reconsideration is now ripe for ruling.

1. PROCEDURAL HISTORY

On June 17, 2013, the Court held a hearing to consider the Defendants’ Partial Motion for Summary Judgment [Dkt. No. 53] and brief in support (“Defendants’ Brief’) [Dkt. No. 54] filed by ProvideRx of Grapevine, LLC, Provider Meds, LP (“PM”), Provider Technologies, Inc. (“PT”), OnSite RX of Phoenix, LLC, W PA Onsite RX, LLC, ProvideRx of Midland, LLC, ProvideRx of Waco, LLC, Pro-videRx of San Antonio, and Reef Gillum as trustee of the Gillum Family Master Heritage Trust (collectively with OnSiteRx, Inc.,2 the “Defendants”), Plaintiff’s Motion for Partial Summary Judgment [Dkt. No. 66] and brief in support (“Plaintiffs Brief’) [Dkt. No. 67] filed by CERx, and the responses and replies related thereto.

At the conclusion of the hearing, this Court orally granted CERx’s request for entry of a judgment against the Gillum Family Master Heritage Trust (“GFMHT”)3 for $10,301,130.81, plus interest at a rate of $4,739.36 per day since March 31, 2013, for sums GFMHT owes CERx under various continuing, unconditional, and unlimited payment guaranties GFMHT executed in favor of CERx covering PM’s debts to CERx. The Court also orally granted CERx’s request for a judgment in this amount against PT, as PM’s general partner, for the debts owed to CERx by PM. Accordingly, on June 26, 2013, this Court entered a Partial Summary Judgment [Dkt. No. 100] reflecting these rulings. The Court also requested supplemental briefing from the parties on several remaining issues at the conclusion of the hearing. By agreement of the parties, the last of those supplemental briefs was submitted on July 3, 2013, and the motions were taken under advisement.

The Court issued the Original Memorandum Opinion on August 2, 2013, in which it found that: (1) the loan documents are unambiguous and, as a matter of law, PM did grant CERx a security interest in all of its IP Assets (as defined on p. 7); (2) although CERx’s security interest attached to PM’s IP Assets, the collateral description contained in the UCC-1 financing statement filed by CERx with the Texas Secretary of State was insufficient to perfect CERx’s security interest in PM’s IP Assets, other than the Patent Applications (as defined on p. 21); (3) pursuant to its Notice of Disposition (as defined on p. 23), CERx only disposed of PM’s Patent Applications; (4) thus, as of its bankruptcy petition date, PM held title to all of its IP Assets, other than the Patent Applications, subject to CERx’s unperfected security interest; and (5) because CERx failed to perfect its non-Patent Application security interests, such interests were unperfected when PM filed its bankruptcy case and are subject to avoidance pursuant to 11 U.S.C. § 544(a)(1). Original Memorandum Opinion at 3. On September 12, 2013, CERx filed the Motion for Reconsideration.

At the conclusion of the January 8, 2014 hearing on the Motion for Reconsideration,4 the Court ordered additional briefing [141]*141on the issues of: (1) whether the Court could read the Transmittal Letter (as defined on p. 22) in conjunction with the Notice of Disposition in order to determine the scope of CERx’s December 13, 2012 disposition of collateral, and (2) whether failure to provide a notice of disposition to all parties required to be given notice under the Texas UCC is grounds to void or otherwise rescind the disposition of collateral. Further, CERx was to include within its post-hearing brief citations to the portions of the summary judgment record connecting the source code referenced in the Transmittal Letter to the Source Code (as defined on p. 20) at issue here. As noted previously, CERx and the Trustees submitted their post-hearing briefs on January 17, 2014. Notably, the Trustees’ brief expressly conceded CERx’s argument on both points:

As a result, with respect to the validity of the foreclosure as to the ownership interest, if any, of Provider Meds, the Trustees believe that the answer to issue (1) is “yes” and that the answer to issue (2) is “no.” Since the Trustees agree with the Court’s tentative rulings with respect to the validity of the foreclosure as to the ownership interests, if any, of Provider Meds, we believe that there is no need to submit briefing on these issues.

Briefing of Legal Issues Discussed at January 8, 2011 Hearing [Dkt. No. 150] at 1. Further, CERx’s post-hearing brief provided the Court with sufficient references to the summary judgment record to show that the source code referenced in the Transmittal Letter is the Source Code at issue here.5 See Plaintiffs Brief Tracing the Sou/rce Code Referred to in CERx’s Transmittal Letter to the Source Code in the Court’s Registry [Dkt. No. 149] at ¶ 5.

II. LEGAL ANALYSIS

A. The Motion for Reconsideration

CERx failed to cite to the rule of procedure under which it would have the Court revisit the Original Memorandum Opinion, only stating that the Motion for Reconsideration is brought to correct a manifest error of law. Plaintiffs Reply Regarding its Amended Motion for Reconsideration or New Trial and Brief (“Reply Regarding Motion for Reconsideration”) [Dkt. No. 142] at 1. To decide which rule of procedure applies to the Motion for Reconsideration, and thus the relevant legal standard to apply, the Court must consider the nature of its decision as set forth in the Original Memorandum Opinion. If it was a final judgment, Fed.R.Civ.P. 59(e) would apply. However, the Original Memorandum Opinion was an interlocutory decision, as it addressed partial summary judgment motions and did not finally dispose of all issues raised in this adversary proceeding. See Moody v. Seaside Lanes, 825 F.2d 81, 85 (5th Cir.1987) (explaining that only the resolution of an entire adversary proceeding is “final”). Interlocutory orders are reconsidered under Fed.R.Civ.P. 54(b), as made applicable to adversary proceedings by Fed. R. Bankr.P.

Related

Cite This Page — Counsel Stack

Bluebook (online)
507 B.R. 132, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cerx-pharmacy-partners-lp-v-provider-meds-lp-in-re-providerx-of-txnb-2014.